Published: 27 December 2021
Author(s): Giustina De Silvestro, Piero Marson, Massimo La Raja, Anna Maria Cattelan, Gabriella Guarnieri, Jacopo Monticelli, Ivo Tiberio, Andrea Vianello, Giorgio Gandini, Gianluca Gessoni, Francesco Fiorin, Corrado Sardella, Laura Astolfi, Mario Saia, Veneto Hospitals
Section: Original article
Convalescent plasma (CP) has been used worldwide to counteract the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)[1]. Since April 2020, it has also been utilised in the treatment of patients with COVID-19 in the Veneto region (Italy), along with all the other available drugs and therapeutic tools[2].
